Literature DB >> 28848883

The COPD Pipeline XXXI.

Nicholas Gross1.   

Abstract

Keywords:  BI1026706; GLPG1837; GSK2269557; PT003; batefenterol; moracin M; nicotine delivery devices; treprostinil

Year:  2016        PMID： 28848883      PMCID： PMC5559161          DOI： 10.15326/jcopdf.3.2.2016.0140

Source DB:  PubMed          Journal:  Chronic Obstr Pulm Dis        ISSN： 2372-952X


× No keyword cloud information.
  5 in total

1.  Evaluation of WO2013136076: two crystalline forms of the phosphatidylinositol 3-kinase-δ inhibitor RV-1729.

Authors:  Peter Norman
Journal:  Expert Opin Ther Pat       Date:  2013-11-27       Impact factor: 6.674

2.  Moracin M from Morus alba L. is a natural phosphodiesterase-4 inhibitor.

Authors:  Shang-Ke Chen; Peng Zhao; Yong-Xian Shao; Zhe Li; Cuixian Zhang; Peiqing Liu; Xixin He; Hai-Bin Luo; Xiaopeng Hu
Journal:  Bioorg Med Chem Lett       Date:  2012-03-21       Impact factor: 2.823

3.  A cystic fibrosis allele encoding missense mutations in both nucleotide binding folds of the cystic fibrosis transmembrane conductance regulator.

Authors:  N Kälin; T Dörk; B Tümmler
Journal:  Hum Mutat       Date:  1992       Impact factor: 4.878

4.  Efficacy and safety of oral treprostinil monotherapy for the treatment of pulmonary arterial hypertension: a randomized, controlled trial.

Authors:  Zhi-Cheng Jing; Keyur Parikh; Tomas Pulido; Carlos Jerjes-Sanchez; R James White; Roblee Allen; Adam Torbicki; Kai-Feng Xu; David Yehle; Kevin Laliberte; Carl Arneson; Lewis J Rubin
Journal:  Circulation       Date:  2013-01-10       Impact factor: 29.690

5.  Population Pharmacokinetics and Pharmacodynamics of GSK961081 (Batefenterol), a Muscarinic Antagonist and β2-Agonist, in Moderate-to-Severe COPD Patients: Substudy of a Randomized Trial.

Authors:  Claire L Ambery; Pascal Wielders; Andrea Ludwig-Sengpiel; Robert Chan; John H Riley
Journal:  Drugs R D       Date:  2015-09
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.